Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Kanyos Bio logo — company profile

Kanyos Bio

Founded 2015 United States Cambridge, United States 1 employees Series Unknown Total: $26.80M Biotechnology, Health Care +1

General Information

Company Name Kanyos Bio
Founded Year 2015
Location United States Cambridge, United States +1
Employees 1
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series Unknown
Social

Get notified when Kanyos Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Kanyos Bio

Kanyos Bio, founded in 2015, focuses on developing antigen-specific immune tolerance technology for type-1 diabetes and celiac disease. The company, headquartered in the United States, originated from EPFL in Switzerland in collaboration with its sister company, Anokion. Kanyos aims to leverage Anokion's immunotechnology expertise and Astellas Pharma's clinical translation experience to develop disease-modifying therapies. The latest funding of $16.40M was obtained through a Venture Round investment on 12 June 2015, with participation from Novartis Venture Fund and Novo Ventures. This unique approach and strong backing from prominent investors position Kanyos Bio as an innovative player in the biotechnology and healthcare industries.

Taxonomy: Antigen-specific immune tolerance technology, Autoimmune indications, Type-1 diabetes, Celiac disease, EPFL, Anokion, Immunotechnology expertise, Clinical translation, Astellas Pharma, Therapies, Disease-modifying, Switzerland, Research and development, Healthcare innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 2
Investor
•••• •••• 		12 Jun 2015
Venture Round •••••• - 29 May 2015

Kanyos Bio Alternatives & Competitors

Kanyos Bio vs
COUR Pharma
COUR Pharma United States

Reprogramming the immune system to restore health in people suffering from autoimmune diseases

Series A
61 employees
Biotechnology, Health and Wellness
Kanyos Bio vs
Anokion
Anokion United States

Restoring normal IMMUNE TOLERANCE to treat autoimmune disease

31 employees
Kanyos Bio vs
Topas Therapeutics GmbH
Topas Therapeutics GmbH Germany

Providing meaningful therapeutic benefit to patients with autoimmune diseases.

Series B
21 employees

FAQ About Kanyos Bio

Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease. Our technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland with our sister company, Anokion. K...
Kanyos Bio was founded in 2015.
Kanyos Bio is headquartered in Cambridge, United States.
Kanyos Bio operates in the following industries: Biotechnology, Health Care, Life Sciences.
Kanyos Bio has approximately 1 employees.
Kanyos Bio has completed 2 funding rounds, raising a total of $26.80M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Kanyos Bio include COUR Pharma, Anokion, Topas Therapeutics GmbH, Celiac Disease Foundation, PredictBGL. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kanyos Bio and COUR Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Kanyos Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy